ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF

The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.

Saved in:
Bibliographic Details
Main Authors SZILLAT, Hauke, HEINELT, Uwe, RACKELMANN, Nils, MENDEZ-PEREZ, Maria, RITTER, Kurt, DEFOSSA, Elisabeth, ZECH, Gernot, MATTER, Hans
Format Patent
LanguageEnglish
French
German
Published 18.09.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
AbstractList The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases and disorders mediated by RIP kinase 1.
Author DEFOSSA, Elisabeth
MENDEZ-PEREZ, Maria
RACKELMANN, Nils
RITTER, Kurt
SZILLAT, Hauke
HEINELT, Uwe
MATTER, Hans
ZECH, Gernot
Author_xml – fullname: SZILLAT, Hauke
– fullname: HEINELT, Uwe
– fullname: RACKELMANN, Nils
– fullname: MENDEZ-PEREZ, Maria
– fullname: RITTER, Kurt
– fullname: DEFOSSA, Elisabeth
– fullname: ZECH, Gernot
– fullname: MATTER, Hans
BookMark eNrjYmDJy89L5WQw8gz2j3CM8vfxdPH0cw1WcAxWCPIM8DZU8PTz8HTyDPEPAor5uSiEBrsqhHi4Brn6u_EwsKYl5hSn8kJpbgYFN9cQZw_d1IL8-NTigsTk1LzUknjXABMTYwMDY3NHQ2MilAAAKncoIQ
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate ISOXAZOLIDINE ALS RIPK1-INHIBITOREN UND VERWENDUNG DAVON
ISOXAZOLIDINES EN TANT QU'INHIBITEURS DE RIPK1 ET LEUR UTILISATION
ExternalDocumentID EP4430037A1
GroupedDBID EVB
ID FETCH-epo_espacenet_EP4430037A13
IEDL.DBID EVB
IngestDate Fri Sep 27 05:31:24 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
German
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_EP4430037A13
Notes Application Number: EP20220817150
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240918&DB=EPODOC&CC=EP&NR=4430037A1
ParticipantIDs epo_espacenet_EP4430037A1
PublicationCentury 2000
PublicationDate 20240918
PublicationDateYYYYMMDD 2024-09-18
PublicationDate_xml – month: 09
  year: 2024
  text: 20240918
  day: 18
PublicationDecade 2020
PublicationYear 2024
RelatedCompanies GENZYME CORPORATION
RelatedCompanies_xml – name: GENZYME CORPORATION
Score 3.5707877
Snippet The present disclosure relates to isoxazolidines and their use as receptor-interacting protein kinase 1 inhibitors, for example in the treatment of diseases...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240918&DB=EPODOC&locale=&CC=EP&NR=4430037A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5KFfWmVbG-2IPkVkzM-xAkyW5I1CYhSSV4Kc2j0EtbbMS_72xMqxe9DbOwL_h29tud_RbgrprppmZUJiJNQYIiq3wdNM3RHLnBrBD14ltnexxq_kR5ytW8B4vtW5hWJ_SzFUdERJWI96Zdr9c_h1i0za3c3BcLdK0evcyiQseOMTyZCGfqWCyOaOQKrouWECaWoshcasVGorSHu2iDZ_-xV4c_Sln_jijeMezHWNmyOYFevRzAobv9eG0AB-PuvhvNDnqbU3gI0ii336KXgPKPMoidkiSInyUShH7gBFmUoC-kZJIykvksYZF3BsRjmeuPsPHpbqBTFu-6KZ9DH_l_fQEEQ2xtaLVSSKKh8KwVrrEnlqJeqaUkzY0hDP-s5vKfsis44jPGkx8k4xr6zftHfYMRtilu27n5AgXQePE
link.rule.ids 230,309,786,891,25585,76894
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5KFetNq2J97kFyKyY2zeMQJI8NWZsXSSrFS2nSFHppi434952NafWit2EW9gXfzn67s98CPMxnqq5ocx2RJiNBGQz5Oqjr_QVyg1kuqvm3znYQKt5YfpkMJy1Y7t7C1Dqhn7U4IiKqQLxX9Xq9-TnEcurcyu1jvkTX-tnNDEdo2DGGJx3h7FgGjSMnsgXbRksIE0OWB1xqxUSidIA7bJ3L7NNXiz9K2fyOKO4JHMZY2ao6hVa56kLH3n281oWjoLnvRrOB3vYMnlgaTcy3yGcO_yiDmClJWDySCAs9ZrEsStAXOmScUpJ5NKGRew7EpZnt9bHx6X6gUxrvuzm4gDby__ISCIbYUlNKOZdETeZZK1xjTyxEdT4sJGmh9aD3ZzVX_5TdQ8fLAn_qs3B0Dcd89ngihKTdQLt6_yhvMdpW-V09T1_cenvk
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=ISOXAZOLIDINES+AS+RIPK1+INHIBITORS+AND+USE+THEREOF&rft.inventor=SZILLAT%2C+Hauke&rft.inventor=HEINELT%2C+Uwe&rft.inventor=RACKELMANN%2C+Nils&rft.inventor=MENDEZ-PEREZ%2C+Maria&rft.inventor=RITTER%2C+Kurt&rft.inventor=DEFOSSA%2C+Elisabeth&rft.inventor=ZECH%2C+Gernot&rft.inventor=MATTER%2C+Hans&rft.date=2024-09-18&rft.externalDBID=A1&rft.externalDocID=EP4430037A1